Objective Assessment of the Long-Term Volumizing Action of a Polycaprolactone-Based Filler
Maria Angelo-Khattar
DOI: https://doi.org/10.2147/CCID.S385202
2022-12-28
Abstract:Maria Angelo-Khattar 1, 2 1 American Academy of Anti-aging Medicine, Dubai, United Arab Emirates; 2 Altaderma Clinic, Dubai, United Arab Emirates Correspondence: Maria Angelo-Khattar, Tel +971506245494, Email Background: The polycaprolactone-based filler, (PCL-1, Ellansé-S), forms part of the recently growing portfolio of biodegradable collagen-stimulating fillers. It is comprised of a suspension of 25– 50 micron diameter microspheres of polycaprolactone (PCL) (30%) in a carboxymethyl cellulose (CMC) gel carrier (70%) and has gained popularity due to its long-term volumizing action. Objective: This study outlines a retrospective case series of nine patients injected with the PCL-1, for volume augmentation in the mid-face. Objective volume calculations were performed with the Canfield Vectra 3D Imaging System at two time points post-implantation, with the objective of determining the longevity of the volumizing effect of the bio-stimulating substance. Results: A clear increase in volume, between 50– 150%, was found in all of the patients at two years, over and above the volume initially injected. All the patients were satisfied with the longevity of the results. Discussion: The PCL-based filler is believed to afford immediate volume restoration due to the CMC gel component and a long-term action due to neo-collagenesis, induced by the PCL microspheres. The CMC gel is known to dissipate within 6– 8 weeks, only to be replaced by new collagen induced by the PCL particles. Thus soft-tissue formation induced by the PCL particles, ultimately leads to a sustained volumizing effect. Conclusion: The PCL-based filler is shown to have a sustained volumizing effects of at least 2 years duration with clear evidence of increase in volume over and above the volume injected, in all of the cases studied. This is indicative of significant neo-collagenesis induced by the PCL microspheres. Keywords: polycaprolactone, biostimulant, Vectra 3D The popularity of fillers for soft-tissue augmentation has increased dramatically in recent years. These medical devices offer impressive aesthetic improvements in facial contouring and rejuvenation, previously only achievable with surgery. According to the latest statistics of the American Academy of Plastic Surgeons (ASPS), 3.4 million soft tissue filler procedures were performed in 2020 and the procedure ranked second amongst the top five cosmetic minimally invasive procedures after neuromodulator injections. 1 The current spectrum of soft-tissue fillers is classified as three main types; permanent non-biodegradable fillers (polyacrylamide, polymethyl methacrylate, silicone), the biodegradable hyaluronic acid products and biodegradable collagen-stimulating polymers. Permanent materials are generally not approved by most countries world-wide due to their potential for inducing long-term and mostly irreversible complications. Several of these fillers are associated with delayed persistent granulomas, sometimes many years post implantation. The hyaluronans are, without a doubt, the most widely used soft-tissue filler substances globally, despite the fact that repeat injections are required to maintain the aesthetic correction. The Hyaluronans are natural compounds and are hence susceptible to metabolism by endogenous hyaluronidase enzyme. Therefore, their longevity has generally been shown to be between 6–12 months. The durability of each hyaluronic acid filler depends upon the extent and type of cross-linkage as well as the concentration and particle size of each specific product. Furthermore, although Hyaluronic acid fillers are of great value in restoring facial volume, they have limited long-term bio-stimulating effects. 2,3 In the early 2000's, the search for biodegradable filler substances with good safety profiles and a longer duration of action, resulted in the development of a new generation of collagen-stimulating fillers. Two of these substances, Radiesse (calcium hydroxylapatite filler, Merz aesthetics) and Sculptra (poly-l-lactic acid, Galderma, USA) were FDA approved in 2001 and 2004, respectively. In 2009, a polycaprolactone-based soft tissue filler (Ellansé, Sinclair Pharma, London, UK) obtained CE marking as a Class III medical device and has gained popularity in Europe and many countries worldwide. All three bio-stimulating compounds are particulate substances between 25–50 microns in size that elicit an inflammatory reaction resulting in encapsulation of the particles and the prevention of their migration. The particles induce type I and type III collagen as well as new soft tissue formation, resulting in long-lasting cosmetic correction, which may in some cases persist for well over 2 years. 4,5 -Abstract Truncated-
dermatology